- Home
- ARQT vs UDMY Comparison
ARQT vs UDMY Comparison
Compare ARQT & UDMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- UDMY
- Stock Information
- Founded
- ARQT 2016
- UDMY 2009
- Country
- ARQT United States
- UDMY United States
- Employees
- ARQT N/A
- UDMY N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- UDMY Other Consumer Services
- Sector
- ARQT Health Care
- UDMY Real Estate
- Exchange
- ARQT Nasdaq
- UDMY Nasdaq
- Market Cap
- ARQT 1.1B
- UDMY 1.2B
- IPO Year
- ARQT 2020
- UDMY 2021
- Fundamental
- Price
- ARQT $13.08
- UDMY $7.49
- Analyst Decision
- ARQT Strong Buy
- UDMY Buy
- Analyst Count
- ARQT 5
- UDMY 10
- Target Price
- ARQT $17.00
- UDMY $10.95
- AVG Volume (30 Days)
- ARQT 1.9M
- UDMY 739.7K
- Earning Date
- ARQT 02-25-2025
- UDMY 02-13-2025
- Dividend Yield
- ARQT N/A
- UDMY N/A
- EPS Growth
- ARQT N/A
- UDMY N/A
- EPS
- ARQT N/A
- UDMY N/A
- Revenue
- ARQT $138,708,000.00
- UDMY $776,168,000.00
- Revenue This Year
- ARQT $215.24
- UDMY $9.33
- Revenue Next Year
- ARQT $53.63
- UDMY $3.30
- P/E Ratio
- ARQT N/A
- UDMY N/A
- Revenue Growth
- ARQT 182.84
- UDMY 10.14
- 52 Week Low
- ARQT $5.38
- UDMY $6.67
- 52 Week High
- ARQT $16.20
- UDMY $14.74
- Technical
- Relative Strength Index (RSI)
- ARQT 41.94
- UDMY 34.57
- Support Level
- ARQT $13.33
- UDMY $7.13
- Resistance Level
- ARQT $15.09
- UDMY $7.88
- Average True Range (ATR)
- ARQT 0.86
- UDMY 0.29
- MACD
- ARQT -0.16
- UDMY -0.07
- Stochastic Oscillator
- ARQT 6.25
- UDMY 12.30
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The Company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.